Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201724
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez Segura, Pedro | - |
dc.contributor.author | Vilariño Quintela, Noelia | - |
dc.contributor.author | Martínez García, María | - |
dc.contributor.author | Barco Berrón, Sonia del | - |
dc.contributor.author | Gironés Sarrió, Regina | - |
dc.contributor.author | García Gómez, Jesús | - |
dc.contributor.author | García Castaño, Almudena | - |
dc.contributor.author | Navarro Martín, Luis Miguel | - |
dc.contributor.author | Gallego Rubio, Oscar | - |
dc.contributor.author | Pineda Losada, Estela | - |
dc.date.accessioned | 2023-09-04T14:57:54Z | - |
dc.date.available | 2023-09-04T14:57:54Z | - |
dc.date.issued | 2023-08-04 | - |
dc.identifier.issn | 1699-3055 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201724 | - |
dc.description.abstract | High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Science and Business Media LLC | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1007/s12094-023-03245-y | - |
dc.relation.ispartof | Clinical and Translational Oncology, 2023, vol. 25, num. 9, p. 2634-2646 | - |
dc.relation.uri | https://doi.org/10.1007/s12094-023-03245-y | - |
dc.rights | cc by (c) Pérez Segura, Pedro et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Glioma | - |
dc.subject.classification | Diagnòstic molecular | - |
dc.subject.classification | Investigació mèdica | - |
dc.subject.other | Gliomas | - |
dc.subject.other | Molecular diagnosis | - |
dc.subject.other | Medicine research | - |
dc.title | SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-04T13:17:32Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37540408 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Intl Journal of Cancer - 2023 - Palomar‐Cros (1).pdf | 770.84 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License